Savara Pharmaceuticals Secures $16,000,000 Series B Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=d8312a88-2ca8-4d97-bf75-0a5a23b8e9f7&Preview=1 - Date
3/20/2013 - Company Name
Savara Pharmaceuticals - Mailing Address
5900 Shepherd Mountain Cove Austin, TX 78730 - Company Description
Savara is a pharmaceutical company developing novel respiratory therapeutics utilizing our proprietary NanoCluster dry powder aerosol drug delivery platform.The aerosols are assembled directly from nanoparticles of an existing therapeutic and delivered via oral pulmonary or nasal routes using off-the-shelf dry powder inhalers. - Website
http://www.savarapharma.com - Transaction Type
Venture Equity - Transaction Amount
$16,000,000 - Transaction Round
Series B - Proceeds Purposes
Savara Pharmaceuticals will use the Series B funds to support a phase IIa clinical program evaluating the efficacy of AeroVancTM (vancomycin hydrochloride inhalation powder) for the treatment of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis (CF) patients. - M&A Terms
- Venture Investor
Pasadena Angels - Venture Investor
Tech Coast Angels - Venture Investor
Central Texas Angel Network - Venture Investor
Keiretsu Forum – Southern California - Venture Investor
North Texas Angel Network
